(-)-(1S)-4-methyl-3-cyclohexenamine | 141484-01-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (-)-(1S)-4-methyl-3-cyclohexenamine
• 英文别名: (1S)-4-methylcyclohex-3-en-1-amine
• CAS: 141484-01-7
• 化学式: C₇H₁₃N
• 分子量: 111.187
• InChiKey: GJIKAJOLWXMKEG-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (-)-(1S)-4-methyl-3-cyclohexenamine 在 吡啶 、 lithium aluminium tetrahydride 、 N,N'-羰基二咪唑 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 23.5h， 生成 (-)-(1S)-N,4-dimethyl-N-(4-methyl-3-cyclohexenyl)-3-pentenamide
  参考文献：
  名称：

  Trichodiene synthase. Synergistic inhibition by inorganic pyrophosphate and aza analogs of the bisabolyl cation.

  摘要：

  A series of aza analogs of the bisabolyl and alpha-terpinyl cations were tested as inhibitors of the sesquiterpene cyclase, trichodiene synthase. Both (R)- and (S)-16 and (R)- and (S)-13 as well as trimethylamine were only weak inhibitors when incubated alone. In the presence of inorganic pyrophosphate, itself a known competitive inhibitor of trichodiene synthase, all five amines showed strong cooperative competitive inhibition with an enhancement factor estimated to be 10-40. The apparent induced inhibition constant alpha-K(j) decreased in going from trimethylamine to the monoterpene analogs 13 and was strongest for the sesquiterpene analogs 16, indicating that both electrostatic and hydrophobic interactions are important in the binding of each intermediate analog. The cyclase showed little discrimination, however, between the individual enantiomers of each inhibitor.

  DOI：

  10.1021/jo00038a040
• 作为产物：
  描述：

  (+)-(1R)-4-methyl-3-cyclohexen-1-ol 在 吡啶 、 lithium aluminium tetrahydride 、 sodium azide 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 29.0h， 生成 (-)-(1S)-4-methyl-3-cyclohexenamine
  参考文献：
  名称：

  Trichodiene synthase. Synergistic inhibition by inorganic pyrophosphate and aza analogs of the bisabolyl cation.

  摘要：

  A series of aza analogs of the bisabolyl and alpha-terpinyl cations were tested as inhibitors of the sesquiterpene cyclase, trichodiene synthase. Both (R)- and (S)-16 and (R)- and (S)-13 as well as trimethylamine were only weak inhibitors when incubated alone. In the presence of inorganic pyrophosphate, itself a known competitive inhibitor of trichodiene synthase, all five amines showed strong cooperative competitive inhibition with an enhancement factor estimated to be 10-40. The apparent induced inhibition constant alpha-K(j) decreased in going from trimethylamine to the monoterpene analogs 13 and was strongest for the sesquiterpene analogs 16, indicating that both electrostatic and hydrophobic interactions are important in the binding of each intermediate analog. The cyclase showed little discrimination, however, between the individual enantiomers of each inhibitor.

  DOI：

  10.1021/jo00038a040

文献信息

• [EN] SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH<br/>[FR] DIAMINOCARBOXAMIDEPYRIMIDINES ET DIAMINOCARBONITRILEPYRIMIDINES SUBSTITUÉES, COMPOSITIONS DE CELLES-CI ET PROCÉDÉS DE TRAITEMENT À L'AIDE DE CELLES-CI
  申请人：SIGNAL PHARM LLC

  公开号：WO2012145569A1

  公开（公告）日：2012-10-26

  Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

  本文提供具有以下结构的二氨基嘧啶化合物：其中R1、R2、R3和R4如本文所定义，包含有效量二氨基嘧啶化合物的组合物，以及用于治疗或预防肝纤维化疾病或通过抑制JNK途径可治疗或预防的疾病的方法。
• SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Bennett Brydon L.

  公开号：US20130029987A1

  公开（公告）日：2013-01-31

  Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R 1 , R 2 , R 3 , and R 4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

  本文提供以下结构的二氨基嘧啶化合物：其中R1、R2、R3和R4的定义如下，在有效量的二氨基嘧啶化合物组成物中，以及用于治疗或预防肝纤维化疾病或可通过抑制JNK途径治疗或预防的疾病的方法。
• Aminodealkenylation: Ozonolysis and copper catalysis convert C(sp ³ )–C(sp ² ) bonds to C(sp ³ )–N bonds
  作者：Zhiqi He、Jose Antonio Moreno、Manisha Swain、Jason Wu、Ohyun Kwon

  DOI：10.1126/science.adi4758

  日期：2023.8.25

  alkene π bond amination. In contrast, analogous functionalization of the adjacent C(sp 3 )–C(sp 2 ) σ bonds is much rarer. Here we report how ozonolysis and copper catalysis under mild reaction conditions enable alkene C(sp 3 )–C(sp 2 ) σ bond–rupturing cross-coupling reactions for the construction of new C(sp 3 )–N bonds. We have used this unconventional transformation for late-stage modification of

  烯烃π键胺化已经投入了大量精力。相比之下，相邻 C（sp 3 ）–C（sp 2 ） σ键的类似官能化要罕见得多。在这里，我们报道了在温和反应条件下的臭氧分解和铜催化如何使烯烃 C（sp 3 ）-C（sp 2 ） σ键破裂交叉偶联反应能够构建新的 C（sp 3 ）-N 键。我们已经将这种非常规转化用于激素、药物试剂、肽和核苷的后期修饰。此外，我们还将大量可用的萜烯和萜类化合物与亲氮试剂偶联，以获得人工萜类生物碱和复杂的手性胺。此外，我们还应用了一种商品化学品 α-甲基苯乙烯作为甲基化试剂，在一个合成步骤中直接从经典核苷制备甲基化核苷。我们的机理研究涉及一个不寻常的铜离子对合作过程。
• Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US10040770B2

  公开（公告）日：2018-08-07

  Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R1, R2, R3, and R4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

  本文提供了具有以下结构的二氨基嘧啶化合物： 其中R1、R2、R3和R4如本文所定义，包含有效量二氨基嘧啶化合物的组合物，以及治疗或预防肝纤维化疾病或可通过抑制JNK通路治疗或预防的病症的方法。
• SUBSTITUTED PYRIDINES AND METHODS OF USE
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US20210154179A1

  公开（公告）日：2021-05-27

  The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.